Clinical trials: Nutritional Evaluation
Healthy
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers
A clinical study to measure the effect of OP-101 after being administered intravenously in healthy volunteers.
- Trial name
- NCT03500627
- Testing
- OP-101
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Orpheris, Inc.
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
The reason for this study is to evaluate if the once-weekly study drug insulin efsitora alfa (LY3209590) is safe and effective compared with daily insulin glargine in participants with Type 2 diabetes (T2D) that have already been…
- Trial name
- QWINT-4 (NCT05462756)
- Testing
- Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100)
- Where
- 81 sites in United States, Argentina and 6 more
- Volunteers
- 730 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes
The purpose of this study is to assess safety and tolerability of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes
- Trial name
- MAD (NCT00747175)
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Hypercholerolemia, Dyslipidemia
Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers
To Evaluate the Safety and Pharmacokinetics of "AJU-C715" and "C715R" in Healthy Adults.
- Trial name
- NCT07581028
- Testing
- Test Drug, Reference Drug
- Where
- South Korea
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- AJU Pharm Co., Ltd.
Type 2 Diabetes Mellitus
Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-398
- Trial name
- NCT04869800
- Testing
- CKD-398, CKD-501, D745
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypercholesterolemia
Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia
The present study is aiming at assessing the efficacy and safety of AVE5530 (25mg and 50mg) in a double-blind comparison with placebo in the management of patients with primary hypercholesterolemia.
- Trial name
- NCT00718965
- Testing
- AVE5530
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 826 people
- Sponsor
- Sanofi
Diabetes Mellitus, Non-Insulin-Dependent
Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)
A clinical study determines the safety and efficacy of sitagliptin (MK0431) in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy
- Trial name
- NCT00758069
- Testing
- sitagliptin phosphate, Comparator: Sitagliptin
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity, Lipid Disorders
A Clinical Study to Evaluate the Safety,Tolerability and PK of ZYT1, Following Oral Administration in Healthy Volunteers
This is a clinical study to evaluate the safety, tolerability and pharmacokinetics of ZYT1, following oral administrations in healthy volunteers. The study shall be divided into four plans as given below: 1.
- Trial name
- NCT01543269
- Testing
- ZYT1
- Where
- India
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Celiac Disease, Coeliac Disease
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole
This is a 3-part first time into human study (FTIH) study for GSK3915393. Parts A and B of the study will evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending and repeat oral doses of GSK3915393 in…
- Trial name
- NCT04604795
- Testing
- GSK3915393 Capsules, GSK3915393 Solution for Infusion, Itraconazole
- Where
- United Kingdom
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Gaucher Disease
A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease
The purpose of this study is to evaluate the safety and efficacy of ISU302 in patients with Type 1 Gaucher disease previously treated with Imiglucerase.
- Trial name
- NCT02053896
- Volunteers
- 5 people
- Sponsor
- ISU Abxis Co., Ltd.
Diabetes Mellitus, Continuous Glucose Monitoring System
To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period
This study is a post-market, prospective, interventional, multicenter clinical trial designed to evaluate the impact of the iCan O3 Continuous Glucose Monitoring (CGM) System on glycemic control in adults with Type 1 (T1D) or…
- Trial name
- DETECT (NCT06904846)
- Testing
- iCan o3 CGM Continuous Glucose Monitoring System
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- Sinocare
Osteopenia
A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women
The main purpose of this study is to assess the safety, tolerability and potential immune response to romosozumab following single subcutaneous (SC; injection under the skin) dose administration in healthy postmenopausal Japanese…
- Trial name
- NCT01101061
- Testing
- Romosozumab
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Amgen
Friedreich Ataxia
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia
In this study, researchers will learn more about omaveloxolone, also known as BIIB141 or SKYCLARYS®. Omaveloxolone is already approved for people with Friedreich's Ataxia (FA) who are 16 years of age or older.
- Trial name
- BRAVE (NCT06953583)
- Testing
- Omaveloxolone
- Where
- 34 sites in United States, Australia and 14 more
- Volunteers
- 255 people
- Sponsor
- Biogen
Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)
The purpose of this study is to evaluate the safety, PK and PD of TAK-906 in participants with Gastroparesis (GP).
- Trial name
- NCT03268941
- Testing
- TAK-906 Maleate, Metaclopramide
- Where
- 9 sites in United States
- Volunteers
- 51 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Overweight , Obesity
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity
This study is a multicenter, randomized, double-blind, placebo-controlled phase II study conducted in China. It aims to evaluate the efficacy and safety of MWN109 injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07791654
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Overweight
Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants
The purpose of this study is to evaluate the effects of RM-493 on mean percent body weight loss, and other weight loss parameters as well as Pharmacokinetic (PK) profile, and ambulatory blood pressure in obese participants.
- Trial name
- NCT01749137
- Testing
- Setmelanotide
- Where
- 6 sites in United States
- Volunteers
- 74 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Diabetes Mellitus, Type 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus
This study will assess the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and pharmacodynamics (explores what a drug does to the body) of multiple doses of JNJ-38431055 in volunteers with type 2…
- Trial name
- NCT00946972
- Volunteers
- 33 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Dyslipidemia, Type II Diabetes
Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes
Randomized, double-blind, active-controlled, multicenter phase 3 trial to evaluate the safety and efficacy of YH14755 in subjects with dyslipidemia and Type II Diabetes.
- Trial name
- NCT02586129
- Testing
- YH14755, Metformin, Rosuvastatin
- Where
- South Korea
- Volunteers
- 249 people
- Sponsor
- Yuhan Corporation
Diabetes, Diabetes Mellitus, Type 2
Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects
This trial is conducted in Europe. The aim of the trial is to evaluate the optimal dosing conditions for semaglutide (a long acting GLP-1 analogue) in healthy male subjects.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01572753
- Testing
- semaglutide
- Where
- Germany
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus
Primary Objective: To assess the dose-response pattern of the glucose consumption (GIR-AUC0-end) of 3 different single doses of Afrezza inhaled Technosphere insulin and of 3 single doses of subcutaneous (SC) insulin lispro in a…
- Trial name
- NCT02470637
- Testing
- SAR439065, Insulin lispro
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Mannkind Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.